Global Gynecology Drugs Market: Industry Analysis and Forecast (2019-2026): By Therapeutics Type, Indication, Distribution Channel and Region.

Global Gynecology Drugs Market: Industry Analysis and Forecast (2019-2026): By Therapeutics Type, Indication, Distribution Channel and Region.

Market Scenario

Global Gynecology Drugs Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2026, at a 7.2% CAGR of around XX% during a forecast period. Global Gynecology Drugs Market Gynecological diseases denote a diverse medical circumstances specific to the female reproductive system. The most common symptoms of gynecologic disorders comprise vaginal itching, vaginal discharge, abnormal vaginal bleeding, breast pain, pelvic pain, and lumps pain. The implication and severity of these symptoms frequently depend on age and with aging. Thus, gynecology drugs treatments is utilized for the medication of several gynecological diseases and symptomsThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The scope of the report includes a detailed study of global and regional markets for Gynecology Drugs with the reasons given for variants in the growth of the industry in certain regions. The implementation of gynecology drugs have increased due to upsurge in frequency of gynecological diseases. Variation in lifestyle of the global female population has progressively enhanced their healthcare necessities. Constant upsurge in awareness about health and well-being has led to an increase in the demand for better gynecological treatments. Identifying this opportunity, several drug producers in global have developed new innovative gynecology treatments that have better efficiency and least side-effects. Additionally, increasing geriatric female population and economic growth are the key factors which offers beneficial opportunity to gynecology drugs market. The report on global Gynecology Drugs market covers segments such as Therapeutics Type, Indication, Distribution Channel and Region. The Therapeutics Type segment includes Hormonal therapy and Non-Hormonal therapy. Among the therapeutics Type, Hormonal therapy is accounted for the largest XX% market share in the global Gynecology Drugs market. Based on Indication, the global Gynecology Drugs market is sub-segmented into Gynecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Gynecology Infections, Polycystic Ovary Syndrome, Contraception (Birth Control), and Others. Amongst them Gynecology Cancers is accounted for the largest XX% market share in the global Gynecology Drugs market. Based on Distribution Channel, the global Gynecology Drugs market is sub-segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Amongst them Hospital Pharmacies are accounted for the largest XX% market share in the global Gynecology Drugs market. Based on regional segment, the global Gynecology Drugs market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is projected to lead the global gynecological drugs market over the forecast period, due to the high disbursement on woman health, extensive research and development activities witnessed in the gynecology field. The rising frequency of polycystic ovarian disease and cervical cancer and increasing approval of gynecological drugs, which are also driving the gynecological drugs market growth. Furthermore, the existence of developed countries, like U.S. and Canada, with technological advanced healthcare amenities and infrastructure are projected to further encourage the gynecological drugs market over the projected period. Europe is expected to trail after North America in terms of growth and be the second largest gynecological drugs market in the years ahead. The extensive research and development labs in the field of gynecology, technological advancements, and numerous gynecological facilities are expected to drive the European gynecological drugs market in the future. The Asia Pacific gynecological drugs market is projected witness a high CAGR over the defined period, due to the existence of developing economies, like India and China, strong healthcare facilities, and promotion of new gynecological drugs apart from the presence of a large patient pool in this region. Moreover, the rising consciousness of gynecological drugs due to the enormous dependence of women on these drugs is also initiating the region’s gynecological drugs market. Key players operating in the Gynecology Drugs market are Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, Sanofi, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Bayer AG, and Johnson & Johnson. These companies have various product offerings and extensive distribution systems across the globe. Furthermore, entry of small players, particularly in developing markets of Asia, is being witnessed. However, rigorous regulatory framework and high-quality standards set by market leaders are expected to restrain the penetration of new entrants in the market. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding global Gynecology Drugs market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the global Gynecology Drugs market.

Scope of the Global Gynecology Drugs Market

Global Gynecology Drugs Market, By Therapeutics Type

• Hormonal therapy • Non-Hormonal therapy

Global Gynecology Drugs Market, By Indication

• Gynecology Cancers • Endometriosis • Female Infertility • Menopausal Disorder • Gynecology Infections • Polycystic Ovary Syndrome • Contraception (Birth Control) • Others

Global Gynecology Drugs Market, By Distribution Channel

• Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

Global Gynecology Drugs Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Gynecology Drugs Market

• Eli Lilly and Company • Pfizer, Inc. • Merck & Co., Inc. • Sanofi • Amgen Inc. • Lupin Pharmaceuticals, Inc. • AstraZeneca • F. Hoffmann-La Roche Ltd. • Allergan Plc. • GlaxoSmithKline plc. • Bayer AG • Johnson & Johnson Global Anti-aging Market 

Table of Contents

Global Gynecology Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gynecology Drugs Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gynecology Drugs Market Analysis and Forecast 6.1. Global Gynecology Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gynecology Drugs Market Analysis and Forecast, By Therapeutics Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gynecology Drugs Market Value Share Analysis, By Therapeutics Type 7.4. Global Gynecology Drugs Market Size (US$ Mn) Forecast, By Therapeutics Type 7.5. Global Gynecology Drugs Market Analysis, By Therapeutics Type 7.6. Global Gynecology Drugs Market Attractiveness Analysis, By Therapeutics Type 8. Global Gynecology Drugs Market Analysis and Forecast, By Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Gynecology Drugs Market Value Share Analysis, By Indication 8.4. Global Gynecology Drugs Market Size (US$ Mn) Forecast, By Indication 8.5. Global Gynecology Drugs Market Analysis, By Indication 8.6. Global Gynecology Drugs Market Attractiveness Analysis, By Indication 9. Global Gynecology Drugs Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Gynecology Drugs Market Value Share Analysis, By Distribution Channel 9.4. Global Gynecology Drugs Market Size (US$ Mn) Forecast, By Distribution Channel 9.5. Global Gynecology Drugs Market Analysis, By Distribution Channel 9.6. Global Gynecology Drugs Market Attractiveness Analysis, By Distribution Channel 10. Global Gynecology Drugs Market Analysis, by Region 10.1. Global Gynecology Drugs Market Value Share Analysis, by Region 10.2. Global Gynecology Drugs Market Size (US$ Mn) Forecast, by Region 10.3. Global Gynecology Drugs Market Attractiveness Analysis, by Region 11. North America Gynecology Drugs Market Analysis 11.1. Key Findings 11.2. North America Gynecology Drugs Market Overview 11.3. North America Gynecology Drugs Market Value Share Analysis, By Therapeutics Type 11.4. North America Gynecology Drugs Market Forecast, By Therapeutics Type 11.4.1. Hormonal therapy 11.4.2. Non-Hormonal therapy 11.5. North America Gynecology Drugs Market Value Share Analysis, By Indication 11.6. North America Gynecology Drugs Market Forecast, By Indication 11.6.1. Gynecology Cancers 11.6.2. Endometriosis 11.6.3. Female Infertility 11.6.4. Menopausal Disorder 11.6.5. Gynecology Infections 11.6.6. Polycystic Ovary Syndrome 11.6.7. Contraception (Birth Control) 11.6.8. Others 11.7. North America Gynecology Drugs Market Value Share Analysis, By Distribution Channel 11.8. North America Gynecology Drugs Market Forecast, By Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Online Pharmacies 11.9. North America Gynecology Drugs Market Value Share Analysis, by Country 11.10. North America Gynecology Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Gynecology Drugs Market Analysis, by Country 11.12. U.S. Gynecology Drugs Market Forecast, By Therapeutics Type 11.12.1. Hormonal therapy 11.12.2. Non-Hormonal therapy 11.13. U.S. Gynecology Drugs Market Forecast, By Indication 11.13.1. Gynecology Cancers 11.13.2. Endometriosis 11.13.3. Female Infertility 11.13.4. Menopausal Disorder 11.13.5. Gynecology Infections 11.13.6. Polycystic Ovary Syndrome 11.13.7. Contraception (Birth Control) 11.13.8. Others 11.14. U.S. Gynecology Drugs Market Forecast, By Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Canada Gynecology Drugs Market Forecast, By Therapeutics Type 11.15.1. Hormonal therapy 11.15.2. Non-Hormonal therapy 11.16. Canada Gynecology Drugs Market Forecast, By Indication 11.16.1. Gynecology Cancers 11.16.2. Endometriosis 11.16.3. Female Infertility 11.16.4. Menopausal Disorder 11.16.5. Gynecology Infections 11.16.6. Polycystic Ovary Syndrome 11.16.7. Contraception (Birth Control) 11.16.8. Others 11.17. Canada Gynecology Drugs Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Pharmacies 11.18. North America Gynecology Drugs Market Attractiveness Analysis 11.18.1. By Therapeutics Type 11.18.2. By Indication 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Gynecology Drugs Market Analysis 12.1. Key Findings 12.2. Europe Gynecology Drugs Market Overview 12.3. Europe Gynecology Drugs Market Value Share Analysis, By Therapeutics Type 12.4. Europe Gynecology Drugs Market Forecast, By Therapeutics Type 12.4.1. Hormonal therapy 12.4.2. Non-Hormonal therapy 12.5. Europe Gynecology Drugs Market Value Share Analysis, By Indication 12.6. Europe Gynecology Drugs Market Forecast, By Indication 12.6.1. Gynecology Cancers 12.6.2. Endometriosis 12.6.3. Female Infertility 12.6.4. Menopausal Disorder 12.6.5. Gynecology Infections 12.6.6. Polycystic Ovary Syndrome 12.6.7. Contraception (Birth Control) 12.6.8. Others 12.7. Europe Gynecology Drugs Market Value Share Analysis, By Distribution Channel 12.8. Europe Gynecology Drugs Market Forecast, By Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Online Pharmacies 12.9. Europe Gynecology Drugs Market Value Share Analysis, by Country 12.10. Europe Gynecology Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Gynecology Drugs Market Analysis, by Country 12.12. Germany Gynecology Drugs Market Forecast, By Therapeutics Type 12.12.1. Hormonal therapy 12.12.2. Non-Hormonal therapy 12.13. Germany Gynecology Drugs Market Forecast, By Indication 12.13.1. Gynecology Cancers 12.13.2. Endometriosis 12.13.3. Female Infertility 12.13.4. Menopausal Disorder 12.13.5. Gynecology Infections 12.13.6. Polycystic Ovary Syndrome 12.13.7. Contraception (Birth Control) 12.13.8. Others 12.14. Germany Gynecology Drugs Market Forecast, By Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail Pharmacies 12.14.3. Online Pharmacies 12.15. U.K. Gynecology Drugs Market Forecast, By Therapeutics Type 12.15.1. Hormonal therapy 12.15.2. Non-Hormonal therapy 12.16. U.K. Gynecology Drugs Market Forecast, By Indication 12.16.1. Gynecology Cancers 12.16.2. Endometriosis 12.16.3. Female Infertility 12.16.4. Menopausal Disorder 12.16.5. Gynecology Infections 12.16.6. Polycystic Ovary Syndrome 12.16.7. Contraception (Birth Control) 12.16.8. Others 12.17. U.K. Gynecology Drugs Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. France Gynecology Drugs Market Forecast, By Therapeutics Type 12.18.1. Hormonal therapy 12.18.2. Non-Hormonal therapy 12.19. France Gynecology Drugs Market Forecast, By Indication 12.19.1. Gynecology Cancers 12.19.2. Endometriosis 12.19.3. Female Infertility 12.19.4. Menopausal Disorder 12.19.5. Gynecology Infections 12.19.6. Polycystic Ovary Syndrome 12.19.7. Contraception (Birth Control) 12.19.8. Others 12.20. France Gynecology Drugs Market Forecast, By Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail Pharmacies 12.20.3. Online Pharmacies 12.21. Italy Gynecology Drugs Market Forecast, By Therapeutics Type 12.21.1. Hormonal therapy 12.21.2. Non-Hormonal therapy 12.22. Italy Gynecology Drugs Market Forecast, By Indication 12.22.1. Gynecology Cancers 12.22.2. Endometriosis 12.22.3. Female Infertility 12.22.4. Menopausal Disorder 12.22.5. Gynecology Infections 12.22.6. Polycystic Ovary Syndrome 12.22.7. Contraception (Birth Control) 12.22.8. Others 12.23. Italy Gynecology Drugs Market Forecast, By Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Online Pharmacies 12.24. Spain Gynecology Drugs Market Forecast, By Therapeutics Type 12.24.1. Hormonal therapy 12.24.2. Non-Hormonal therapy 12.25. Spain Gynecology Drugs Market Forecast, By Indication 12.25.1. Gynecology Cancers 12.25.2. Endometriosis 12.25.3. Female Infertility 12.25.4. Menopausal Disorder 12.25.5. Gynecology Infections 12.25.6. Polycystic Ovary Syndrome 12.25.7. Contraception (Birth Control) 12.25.8. Others 12.26. Spain Gynecology Drugs Market Forecast, By Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail Pharmacies 12.26.3. Online Pharmacies 12.27. Rest of Europe Gynecology Drugs Market Forecast, By Therapeutics Type 12.27.1. Hormonal therapy 12.27.2. Non-Hormonal therapy 12.28. Rest of Europe Gynecology Drugs Market Forecast, By Indication 12.28.1. Gynecology Cancers 12.28.2. Endometriosis 12.28.3. Female Infertility 12.28.4. Menopausal Disorder 12.28.5. Gynecology Infections 12.28.6. Polycystic Ovary Syndrome 12.28.7. Contraception (Birth Control) 12.28.8. Others 12.29. Rest of Europe Gynecology Drugs Market Forecast, By Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail Pharmacies 12.29.3. Online Pharmacies 12.30. Europe Gynecology Drugs Market Attractiveness Analysis 12.30.1. By Therapeutics Type 12.30.2. By Indication 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Gynecology Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Gynecology Drugs Market Overview 13.3. Asia Pacific Gynecology Drugs Market Value Share Analysis, By Therapeutics Type 13.4. Asia Pacific Gynecology Drugs Market Forecast, By Therapeutics Type 13.4.1. Hormonal therapy 13.4.2. Non-Hormonal therapy 13.5. Asia Pacific Gynecology Drugs Market Value Share Analysis, By Indication 13.6. Asia Pacific Gynecology Drugs Market Forecast, By Indication 13.6.1. Gynecology Cancers 13.6.2. Endometriosis 13.6.3. Female Infertility 13.6.4. Menopausal Disorder 13.6.5. Gynecology Infections 13.6.6. Polycystic Ovary Syndrome 13.6.7. Contraception (Birth Control) 13.6.8. Others 13.7. Asia Pacific Gynecology Drugs Market Value Share Analysis, By Distribution Channel 13.8. Asia Pacific Gynecology Drugs Market Forecast, By Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Online Pharmacies 13.9. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Gynecology Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Gynecology Drugs Market Analysis, by Country 13.12. China Gynecology Drugs Market Forecast, By Therapeutics Type 13.12.1. Hormonal therapy 13.12.2. Non-Hormonal therapy 13.13. China Gynecology Drugs Market Forecast, By Indication 13.13.1. Gynecology Cancers 13.13.2. Endometriosis 13.13.3. Female Infertility 13.13.4. Menopausal Disorder 13.13.5. Gynecology Infections 13.13.6. Polycystic Ovary Syndrome 13.13.7. Contraception (Birth Control) 13.13.8. Others 13.14. China Gynecology Drugs Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. India Gynecology Drugs Market Forecast, By Therapeutics Type 13.15.1. Hormonal therapy 13.15.2. Non-Hormonal therapy 13.16. India Gynecology Drugs Market Forecast, By Indication 13.16.1. Gynecology Cancers 13.16.2. Endometriosis 13.16.3. Female Infertility 13.16.4. Menopausal Disorder 13.16.5. Gynecology Infections 13.16.6. Polycystic Ovary Syndrome 13.16.7. Contraception (Birth Control) 13.16.8. Others 13.17. India Gynecology Drugs Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Japan Gynecology Drugs Market Forecast, By Therapeutics Type 13.18.1. Hormonal therapy 13.18.2. Non-Hormonal therapy 13.19. Japan Gynecology Drugs Market Forecast, By Indication 13.19.1. Gynecology Cancers 13.19.2. Endometriosis 13.19.3. Female Infertility 13.19.4. Menopausal Disorder 13.19.5. Gynecology Infections 13.19.6. Polycystic Ovary Syndrome 13.19.7. Contraception (Birth Control) 13.19.8. Others 13.20. Japan Gynecology Drugs Market Forecast, By Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Online Pharmacies 13.21. ASEAN Gynecology Drugs Market Forecast, By Therapeutics Type 13.21.1. Hormonal therapy 13.21.2. Non-Hormonal therapy 13.22. ASEAN Gynecology Drugs Market Forecast, By Indication 13.22.1. Gynecology Cancers 13.22.2. Endometriosis 13.22.3. Female Infertility 13.22.4. Menopausal Disorder 13.22.5. Gynecology Infections 13.22.6. Polycystic Ovary Syndrome 13.22.7. Contraception (Birth Control) 13.22.8. Others 13.23. ASEAN Gynecology Drugs Market Forecast, By Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Online Pharmacies 13.24. Rest of Asia Pacific Gynecology Drugs Market Forecast, By Therapeutics Type 13.24.1. Hormonal therapy 13.24.2. Non-Hormonal therapy 13.25. Rest of Asia Pacific Gynecology Drugs Market Forecast, By Indication 13.25.1. Gynecology Cancers 13.25.2. Endometriosis 13.25.3. Female Infertility 13.25.4. Menopausal Disorder 13.25.5. Gynecology Infections 13.25.6. Polycystic Ovary Syndrome 13.25.7. Contraception (Birth Control) 13.25.8. Others 13.26. Rest of Asia Pacific Gynecology Drugs Market Forecast, By Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Online Pharmacies 13.27. Asia Pacific Gynecology Drugs Market Attractiveness Analysis 13.27.1. By Therapeutics Type 13.27.2. By Indication 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Gynecology Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Gynecology Drugs Market Overview 14.3. Middle East & Africa Gynecology Drugs Market Value Share Analysis, By Therapeutics Type 14.4. Middle East & Africa Gynecology Drugs Market Forecast, By Therapeutics Type 14.4.1. Hormonal therapy 14.4.2. Non-Hormonal therapy 14.5. Middle East & Africa Gynecology Drugs Market Value Share Analysis, By Indication 14.6. Middle East & Africa Gynecology Drugs Market Forecast, By Indication 14.6.1. Gynecology Cancers 14.6.2. Endometriosis 14.6.3. Female Infertility 14.6.4. Menopausal Disorder 14.6.5. Gynecology Infections 14.6.6. Polycystic Ovary Syndrome 14.6.7. Contraception (Birth Control) 14.6.8. Others 14.7. Middle East & Africa Gynecology Drugs Market Value Share Analysis, By Distribution Channel 14.8. Middle East & Africa Gynecology Drugs Market Forecast, By Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Online Pharmacies 14.9. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Gynecology Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Gynecology Drugs Market Analysis, by Country 14.12. GCC Gynecology Drugs Market Forecast, By Therapeutics Type 14.12.1. Hormonal therapy 14.12.2. Non-Hormonal therapy 14.13. GCC Gynecology Drugs Market Forecast, By Indication 14.13.1. Gynecology Cancers 14.13.2. Endometriosis 14.13.3. Female Infertility 14.13.4. Menopausal Disorder 14.13.5. Gynecology Infections 14.13.6. Polycystic Ovary Syndrome 14.13.7. Contraception (Birth Control) 14.13.8. Others 14.14. GCC Gynecology Drugs Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Online Pharmacies 14.15. South Africa Gynecology Drugs Market Forecast, By Therapeutics Type 14.15.1. Hormonal therapy 14.15.2. Non-Hormonal therapy 14.16. South Africa Gynecology Drugs Market Forecast, By Indication 14.16.1. Gynecology Cancers 14.16.2. Endometriosis 14.16.3. Female Infertility 14.16.4. Menopausal Disorder 14.16.5. Gynecology Infections 14.16.6. Polycystic Ovary Syndrome 14.16.7. Contraception (Birth Control) 14.16.8. Others 14.17. South Africa Gynecology Drugs Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. Rest of Middle East & Africa Gynecology Drugs Market Forecast, By Therapeutics Type 14.18.1. Hormonal therapy 14.18.2. Non-Hormonal therapy 14.19. Rest of Middle East & Africa Gynecology Drugs Market Forecast, By Indication 14.19.1. Gynecology Cancers 14.19.2. Endometriosis 14.19.3. Female Infertility 14.19.4. Menopausal Disorder 14.19.5. Gynecology Infections 14.19.6. Polycystic Ovary Syndrome 14.19.7. Contraception (Birth Control) 14.19.8. Others 14.20. Rest of Middle East & Africa Gynecology Drugs Market Forecast, By Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Online Pharmacies 14.21. Middle East & Africa Gynecology Drugs Market Attractiveness Analysis 14.21.1. By Therapeutics Type 14.21.2. By Indication 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Gynecology Drugs Market Analysis 15.1. Key Findings 15.2. South America Gynecology Drugs Market Overview 15.3. South America Gynecology Drugs Market Value Share Analysis, By Therapeutics Type 15.4. South America Gynecology Drugs Market Forecast, By Therapeutics Type 15.4.1. Hormonal therapy 15.4.2. Non-Hormonal therapy 15.5. South America Gynecology Drugs Market Value Share Analysis, By Indication 15.6. South America Gynecology Drugs Market Forecast, By Indication 15.6.1. Gynecology Cancers 15.6.2. Endometriosis 15.6.3. Female Infertility 15.6.4. Menopausal Disorder 15.6.5. Gynecology Infections 15.6.6. Polycystic Ovary Syndrome 15.6.7. Contraception (Birth Control) 15.6.8. Others 15.7. South America Gynecology Drugs Market Value Share Analysis, By Distribution Channel 15.8. South America Gynecology Drugs Market Forecast, By Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Online Pharmacies 15.9. South America Gynecology Drugs Market Value Share Analysis, by Country 15.10. South America Gynecology Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Gynecology Drugs Market Analysis, by Country 15.12. Brazil Gynecology Drugs Market Forecast, By Therapeutics Type 15.12.1. Hormonal therapy 15.12.2. Non-Hormonal therapy 15.13. Brazil Gynecology Drugs Market Forecast, By Indication 15.13.1. Gynecology Cancers 15.13.2. Endometriosis 15.13.3. Female Infertility 15.13.4. Menopausal Disorder 15.13.5. Gynecology Infections 15.13.6. Polycystic Ovary Syndrome 15.13.7. Contraception (Birth Control) 15.13.8. Others 15.14. Brazil Gynecology Drugs Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Online Pharmacies 15.15. Mexico Gynecology Drugs Market Forecast, By Therapeutics Type 15.15.1. Hormonal therapy 15.15.2. Non-Hormonal therapy 15.16. Mexico Gynecology Drugs Market Forecast, By Indication 15.16.1. Gynecology Cancers 15.16.2. Endometriosis 15.16.3. Female Infertility 15.16.4. Menopausal Disorder 15.16.5. Gynecology Infections 15.16.6. Polycystic Ovary Syndrome 15.16.7. Contraception (Birth Control) 15.16.8. Others 15.17. Mexico Gynecology Drugs Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. Rest of South America Gynecology Drugs Market Forecast, By Therapeutics Type 15.18.1. Hormonal therapy 15.18.2. Non-Hormonal therapy 15.19. Rest of South America Gynecology Drugs Market Forecast, By Indication 15.19.1. Gynecology Cancers 15.19.2. Endometriosis 15.19.3. Female Infertility 15.19.4. Menopausal Disorder 15.19.5. Gynecology Infections 15.19.6. Polycystic Ovary Syndrome 15.19.7. Contraception (Birth Control) 15.19.8. Others 15.20. Rest of South America Gynecology Drugs Market Forecast, By Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Online Pharmacies 15.21. South America Gynecology Drugs Market Attractiveness Analysis 15.21.1. By Therapeutics Type 15.21.2. By Indication 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Route of Administrations and R&D investment 16.2.2. New Indication Launches and Indication Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Route of Administrations 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Eli Lilly and Company 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Indication Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Pfizer, Inc. 16.3.3. Merck & Co., Inc. 16.3.4. Sanofi 16.3.5. Amgen Inc. 16.3.6. Lupin Pharmaceuticals, Inc. 16.3.7. AstraZeneca 16.3.8. F. Hoffmann-La Roche Ltd. 16.3.9. Allergan Plc. 16.3.10. GlaxoSmithKline plc. 16.3.11. Bayer AG 16.3.12. Johnson & Johnson 17. Primary Key Insights

About This Report

Report ID36456
Category Healthcare
Published DateNov 2019
No of Pages296
Contact Us
Call Now